Your Article Summary
See Latest ArticlesMedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
Medimmune, 06/30/09
MedImmune announced the expansion of the MedImmune Assistance Program for Synagis designed to provide the antibody at no cost to qualifying patients who lack health insurance and whose family household income falls within a certain range of the Federal Poverty Level guidelines established by the U.S. Department of Health and Human Services. Synagis is a biologic medicine known as a monoclonal antibody administered monthly to high-risk infants to prevent serious lower respiratory tract infection caused by respiratory syncytial virus, a leading cause of viral respiratory infection among infants.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
deCODE Discovers A Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin
deCODE genetics, 12/17/09
The Medtronic Foundation Offers Grants to Schools Participating in Online Sudden Cardiac Arrest Response Training
Medtronic, 12/17/09
AstraZeneca and the University of Virginia sign strategic research collaboration to develop novel treatments for cardiovascular disease
AstraZeneca, 12/16/09